Cargando…
Assessment of BIV1-CovIran inactivated vaccine–elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern
OBJECTIVES: The BIV1-CovIran vaccine is highly effective against COVID-19. The neutralizing potency of all SARS-CoV-2 vaccines seems to be decreased against variants of concern. We assessed the sensitivity of the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants to neutralizing antibod...
Autores principales: | Salehi, Mohammadreza, Hosseini, Hamed, Jamshidi, Hamid Reza, Jalili, Hasan, Tabarsi, Payam, Mohraz, Minoo, Karimi, Hesam, Lotfinia, Majid, Aalizadeh, Reza, Mohammadi, Mehrdad, Ramazi, Shahin, Abdoli, Asghar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893932/ https://www.ncbi.nlm.nih.gov/pubmed/35248745 http://dx.doi.org/10.1016/j.cmi.2022.02.030 |
Ejemplares similares
-
The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies
por: Shafaati, Maryam, et al.
Publicado: (2023) -
Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial
por: Mohraz, Minoo, et al.
Publicado: (2023) -
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults
por: Mohraz, Minoo, et al.
Publicado: (2022) -
Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial
Publicado: (2023) -
Correction: Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults
Publicado: (2022)